ArticleBMC pregnancy and childbirth2025
Retrospective cohort study on cumulative live birth rate of in vitro fertilization/intracytoplasmic sperm injection after multiple complete cycles in patients with diminished ovarian reserve.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiminished ovarian reserve refers to the decrease in the quantity and quality of oocytes in the ovary which may cause poor fertility outcomes even with the help of assisted reproductive techniques. Most patients will undergo multiple cycles of IVF treatments. Compared to the live birth rate of a single oocyte retrieval cycle, the cumulative live birth rate across multiple cycles provides a more comprehensive reflection of treatment efficiency and a patient's long-term outcomes, holding the following importance for clinical decision-making. This study aimed to evaluate the cumulative live birth rate of in vitro fertilization / intracytoplasmic sperm injection after multiple complete cycles in patients with diminished ovarian reserve.
methodsWe performed a retrospective cohort study in female patients with diminished ovarian reserve undergoing in vitro fertilization / intracytoplasmic sperm injection cycle during the period from January 2016 to December 2020. All patients were followed up for 3 years until either discontinuation of treatments or delivery of one or more live infants. The conservative estimate of cumulative live birth rate and the optimal estimate of cumulative live birth rate were calculated.
resultsA total of 343 patients were included in this study, including 996 oocyte retrieval cycles. After one or more cycles of treatments, a total of 141 couples achieved live births during the study period, with a conservative estimate cumulative live birth rate of 41.1% and a optimistic estimate cumulative live birth rate of 81.0%. For women aged < 35 and 35 ~ 39, after 6 oocyte retrieval cycles, the conservative/optimistic estimates of the cumulative live birth rates reached 57.4/ 82.7% and 41.1/ 64.8%, respectively. For elderly women equal or over 40 years old, the conservative/optimistic estimates of the cumulative live birth rates after 6 oocyte retrieval cycles were only 14.7/ 26.0%. The multivariate analysis results showed that: age and the number of oocytes retrieved per cycle were significantly associated with live birth outcomes.
conclusionFor female diminished ovarian reserve patients younger than 40 years old, multiple cycles in vitro fertilization / intracytoplasmic sperm injection treatments can help to achieve satisfactory success rates. As for elder patients aged 40 or above, more than 4 cycles of in vitro fertilization / intracytoplasmic sperm injection may have limited benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.